Skip to main content
Signal8
Launch Terminal

Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc.

NASDAQ:ELVNHealthcare
-1.84%$44.25
AH$44.25+0.00%vs close
Mkt Cap$3.24B
Float56.95M
O/S73.27M
Vol
$ Vol
RVOL
Inst Own-
SI16.4%
Earnings
Dilution
Enliven Therapeutics, Inc. logoNASDAQ:ELVN$44.25-1.84%
Phase Distribution
6 lead-sponsored trials·5 active·0 completed
Phase 14
Phase 21
Phase 31
(5 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting2
Active, not recruiting3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Not yet recruiting

    A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

    ELVN-001, TKI

    Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive +1

    Enrollment
    450
    Start
    Dec 2026est.
    Primary Completion
    Dec 2028est.
    Completion
    Jul 2033est.
    NCT07905183
  • Phase 2
    Active, not recruiting

    An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

    IMR-687

    Sickle Cell Disease

    Enrollment
    30
    Start
    May 2019
    Primary Completion
    Mar 2025est.
    Completion
    Mar 2025est.
    NCT04053803
  • Phase 1
    Recruiting

    A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

    ELVN-001

    Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive +1

    Enrollment
    250
    Start
    May 2022
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT05304377
  • Phase 1
    Active, not recruiting

    ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

    ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki

    HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer +2

    Enrollment
    198
    Start
    Mar 2023
    Primary Completion
    Jul 2026est.
    Completion
    Jul 2026est.
    NCT05650879
  • Phase 1
    Active, not recruiting

    ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

    ELVN-002, Trastuzumab

    HER2-positive Breast Cancer, HER2-positive Gastric Cancer +3

    Enrollment
    275
    Start
    May 2024
    Primary Completion
    Jan 2027est.
    Completion
    Jul 2028est.
    NCT06328738
  • Phase 1
    Recruiting

    ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

    ELVN-001

    CML (Chronic Myelogenous Leukemia), Chronic Phase CML

    Enrollment
    21
    Start
    Jan 2025
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2028est.
    NCT06787144
Search ClinicalTrials.gov for “Enliven Therapeutics”